Effect of polypharmacy on healthcare costs in hospitalized patients diagnosed with hypertension and diabetes mellitus in a tertiary care teaching hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262871Keywords:
Diabetes mellitus, Hypertension, Polypharmacy, Healthcare costsAbstract
Background: Hospitalised patients with diabetes mellitus and hypertension, particularly older adults, often have multiple comorbidities requiring polypharmacy. While the clinical consequences of polypharmacy are well documented, its economic impact, including healthcare expenditure, financial burden, and cost-related medication nonadherence, remains underexplored in resource-limited settings. Objectives of the study were to evaluate the association of polypharmacy and comorbidities with healthcare costs, financial burden, and cost-related medication non-adherence among hospitalised patients with diabetes mellitus and hypertension.
Methods: A cross-sectional study was conducted among 180 hospitalised patients with diabetes mellitus and hypertension, with or without comorbidities, at a tertiary care teaching hospital. Data were collected using a validated proforma through patient interviews and medical records. Polypharmacy was defined as the use of ≥6 medications. Healthcare costs were categorized into direct medical, direct non-medical and indirect costs. Financial burden was estimated by comparing healthcare expenditure to income and cost-related medication nonadherence was assessed using a structured questionnaire. Statistical significance was set at p<0.05.
Results: Polypharmacy was observed in 94.4% of patients. Those with polypharmacy incurred significantly higher direct medical (INR 8,380.24 versus INR 4,705; p<0.001), direct non-medical (INR 4,388.22 versus INR 1,174; p<0.001), and indirect costs (INR 2,638.82 versus INR 1,200; p=0.038). Patients with comorbidities had higher direct medical and non-medical costs, greater financial burden (70.29% versus 52.5%), and higher cost-related medication nonadherence (65.34% versus 32.5%).
Conclusions: Polypharmacy and comorbidities substantially increase healthcare costs, financial burden, and cost-related medication nonadherence among hospitalised patients with diabetes and hypertension. Strategies to optimize medication use and improve financial support are essential to reduce these burdens.
References
World Health Organization (WHO). Non-communicable diseases. 2023. Available at: https:// www.who.int/news-room/fact-sheets/detail/noncomm unicable-diseases. Accessed on 08 May 2026.
Balasubramanyam M. Hypertension in India needs attention, detection and correction. Healthcare Radius. 2024. Available at: https://www.healthcareradius. in/clinical/treatment/hypertension-in-india-needs-attention-detection-and-correction. Accessed on 08 May 2026.
International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels, Belgium. 2024. Available at: IDF Diabetes Atlas. 11th ed. Brussels, Belgium: International Diabetes Federation. Accessed on 08 May 2026.
Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57(5):891-7.
Khunti K, Chudasama Y, Gregg EW, Kamkuemah M, Misra S, Suls J, et al. Diabetes and multiple long-term conditions: a review of our current global health challenge. Diabetes Care. 2023;46(12):2092-104.
Saeed Z, Ostrominski JW, Aroda VR. Polypharmacy in type 2 diabetes: appropriate or a cause for concern? Diabetes Care. 2024;47(12):2104-6.
Sapkota B, Shakya S, Sah S, Chaudhary NK, Tamang B, Karki SS. Economic implications of polypharmacy in Nepal: a multicentre community-based study. medRxiv. 2020;1:30.
Zhao Y, Wang J, Zhu X, Zhang X, Zhang Y, Zhang W, et al. Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study. BMC Geriatr. 2023;23(1):423.
Butt MD, Ong SC, Wahab MU, Rasool MF, Saleem F,. Cost of illness analysis of type 2 diabetes mellitus: findings from a lower-middle income country. Int J Environ Res Public Health. 2022;19:12611.
Daunt R, Curtin D, O’Mahony D. Polypharmacy stewardship: a novel approach to tackle a major public health crisis. Lancet Healthy Longev. 2023;4(5):e320-1.
Scotti S, Scotti L, Galimberti F, Xie S, Casula M, Olmastroni E. Operational definitions of polypharmacy and their association with all-cause hospitalization risk: a conceptual framework using administrative databases. Pharmacy (Basel). 2025;13(1):15.
Moura CS, Acúrcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-72.
Piao Z, Oh KS, Han E. Healthcare burden and clinical outcomes of polypharmacy in older adults: a population-based cohort study in South Korea. Arch Public Health. 2025;83(1):1-10.
Páez NA, Torres CC, Campos de Aldana MS, Solano S, Quintero N, Chaparro OL. Direct and indirect costs of caring for patients with chronic non-communicable diseases. Aquichan. 2020;20(2):e2022.
Bloom DE, Chen S, Kuhn M, McGovern ME, Oxley L, Prettner K. The economic burden of chronic diseases: estimates and projections for China, Japan, and South Korea. J Econ Ageing. 2020;17:100163.
Kim EJ, Jung SW. Sensitivity analysis of the economic burden using social insurance claim data. J Public Health Epidemiol. 2016;8(12):351-7.
Alshammari AM, Elnaem MH, Ong SC. Evaluating the economic impact of diabetes mellitus: a hospital-centric cost analysis in Hail, Saudi Arabia. Clinicoecon Outcomes Res. 2025;17:473-84.
Mutowo MP, Lorgelly PK, Laxy M, Renzaho AM, Mangwiro JC, Owen AJ. The hospitalization costs of diabetes and hypertension complications in Zimbabwe: estimations and correlations. J Diabetes Res. 2016;2016:9754230.
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-37.
Kieu TTM, Trinh HN, Pham HTK, Nguyen T, Ng JYS. Direct non-medical and indirect costs of diabetes and its associated complications in Vietnam: an estimation using national health insurance claims from a cross-sectional survey. BMJ Open. 2020;10:e032303.
Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl Health Econ Health Policy. 2018;16(5):609-32.
Downloads
Published
How to Cite
Issue
Section
